1256 related articles for article (PubMed ID: 19926371)
1. Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and exercise in obese patients with CKD: 2-year follow-up.
MacLaughlin HL; Cook SA; Kariyawasam D; Roseke M; van Niekerk M; Macdougall IC
Am J Kidney Dis; 2010 Jan; 55(1):69-76. PubMed ID: 19926371
[TBL] [Abstract][Full Text] [Related]
2. A structured weight management programme can achieve improved functional ability and significant weight loss in obese patients with chronic kidney disease.
Cook SA; MacLaughlin H; Macdougall IC
Nephrol Dial Transplant; 2008 Jan; 23(1):263-8. PubMed ID: 17977872
[TBL] [Abstract][Full Text] [Related]
3. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
[TBL] [Abstract][Full Text] [Related]
4. Influence of obesity on progression of non-diabetic chronic kidney disease: a retrospective cohort study.
Othman M; Kawar B; El Nahas AM
Nephron Clin Pract; 2009; 113(1):c16-23. PubMed ID: 19590231
[TBL] [Abstract][Full Text] [Related]
5. Prehypertension, obesity, and risk of kidney disease: 20-year follow-up of the HUNT I study in Norway.
Munkhaugen J; Lydersen S; Widerøe TE; Hallan S
Am J Kidney Dis; 2009 Oct; 54(4):638-46. PubMed ID: 19515474
[TBL] [Abstract][Full Text] [Related]
6. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L
Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
[TBL] [Abstract][Full Text] [Related]
7. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.
Richelsen B; Tonstad S; Rössner S; Toubro S; Niskanen L; Madsbad S; Mustajoki P; Rissanen A
Diabetes Care; 2007 Jan; 30(1):27-32. PubMed ID: 17192328
[TBL] [Abstract][Full Text] [Related]
8. Association of body mass index with decline in residual kidney function after initiation of dialysis.
Drechsler C; de Mutsert R; Grootendorst DC; Boeschoten EW; Krediet RT; le Cessie S; Wanner C; Dekker FW;
Am J Kidney Dis; 2009 Jun; 53(6):1014-23. PubMed ID: 19217702
[TBL] [Abstract][Full Text] [Related]
9. Effect of orlistat on cardiovascular disease risk in obese adults.
Swinburn BA; Carey D; Hills AP; Hooper M; Marks S; Proietto J; Strauss BJ; Sullivan D; Welborn TA; Caterson ID
Diabetes Obes Metab; 2005 May; 7(3):254-62. PubMed ID: 15811142
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients.
Kaya A; Aydin N; Topsever P; Filiz M; Oztürk A; Dağar A; Kilinç E; Ekmekcioglu C
Biomed Pharmacother; 2004 Dec; 58(10):582-7. PubMed ID: 15589067
[TBL] [Abstract][Full Text] [Related]
11. Bariatric surgery and progression of chronic kidney disease.
Navaneethan SD; Yehnert H
Surg Obes Relat Dis; 2009; 5(6):662-5. PubMed ID: 19359221
[TBL] [Abstract][Full Text] [Related]
12. GFR, body mass index, and low high-density lipoprotein concentration in adults with and without CKD.
Lo JC; Go AS; Chandra M; Fan D; Kaysen GA
Am J Kidney Dis; 2007 Oct; 50(4):552-8. PubMed ID: 17900454
[TBL] [Abstract][Full Text] [Related]
13. Effect of a low- versus moderate-protein diet on progression of CKD: follow-up of a randomized controlled trial.
Cianciaruso B; Pota A; Bellizzi V; Di Giuseppe D; Di Micco L; Minutolo R; Pisani A; Sabbatini M; Ravani P
Am J Kidney Dis; 2009 Dec; 54(6):1052-61. PubMed ID: 19800722
[TBL] [Abstract][Full Text] [Related]
14. The long-term influence of orlistat on dietary intake in obese subjects with components of metabolic syndrome.
Svendsen M; Helgeland M; Tonstad S
J Hum Nutr Diet; 2009 Feb; 22(1):55-63. PubMed ID: 19192027
[TBL] [Abstract][Full Text] [Related]
15. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
[TBL] [Abstract][Full Text] [Related]
16. Association between body mass index and body fat in chronic kidney disease stages 3 to 5, hemodialysis, and peritoneal dialysis patients.
Leinig C; Pecoits-Filho R; Nascimento MM; Gonçalves S; Riella MC; Martins C
J Ren Nutr; 2008 Sep; 18(5):424-9. PubMed ID: 18721737
[TBL] [Abstract][Full Text] [Related]
17. The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss.
Rowe R; Cowx M; Poole C; McEwan P; Morgan C; Walker M
Curr Med Res Opin; 2005 Nov; 21(11):1885-90. PubMed ID: 16307710
[TBL] [Abstract][Full Text] [Related]
18. Continuous ambulatory peritoneal dialysis patients are unable to increase dietary intake to recommended levels.
Sutton D; Higgins B; Stevens JM
J Ren Nutr; 2007 Sep; 17(5):329-35. PubMed ID: 17720102
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the Modification of Diet in Renal Disease and Cockcroft-Gault equations for dosing antimicrobials.
Hermsen ED; Maiefski M; Florescu MC; Qiu F; Rupp ME
Pharmacotherapy; 2009 Jun; 29(6):649-55. PubMed ID: 19476418
[TBL] [Abstract][Full Text] [Related]
20. Implementing KDOQI CKD definition and staging guidelines in Southern California Kaiser Permanente.
Rutkowski M; Mann W; Derose S; Selevan D; Pascual N; Diesto J; Crooks P
Am J Kidney Dis; 2009 Mar; 53(3 Suppl 3):S86-99. PubMed ID: 19231766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
